INMAR RX SOLUTIONS FILES COMPLAINT IN THE U.S. DISTRICT COURT AGAINST THE U.S. DEPARTMENT OF JUSTICE AND DEA.

In response to the administrative action taken by the DEA on September 27, 2023, Inmar Rx Solutions, Inc. took legal action to seek clarity and a resolution with the U.S. Drug Enforcement Administration (DEA) and filed a complaint on December 29, 2023 in the U.S. District Court for the Northern District of Texas, Dallas against the U.S. Department of Justice and DEA. This legal action is in response to the administrative action (Order to Show Cause or “OSC”) taken by the DEA on September 27, 2023 and serves our common interest in driving clear priorities.

Inmar Intelligence and the DEA share a long-term commitment to the mission of safe control and disposal of controlled substances. Inmar Rx Solutions, Inc. plays a critical role in our country’s drug supply chain, helping to mitigate the risk of diversion of millions of medications every day.

COMMITTED TO THE HIGHEST LEVEL OF SAFETY

We are focused on continuing to serve the more than 35,000 pharmacies and over 5,000 U.S. hospitals who depend on us, while we continue working closely with the DEA to address and resolve this administrative matter. Our commitment to upholding the highest level of safety and security in our operations remains as strong as ever.

We believe that the DEA’s concerns are the result of misunderstanding about how we operate. Importantly, the DEA has not alleged, and nothing in the administrative action relates to, any diversion or lack of control of Rx products from Inmar’s Grand Prairie facility. Nor is there any allegation or suggestion that Inmar has not filed timely theft/loss reports with the DEA (over 99% of which are losses that Inmar identifies, occurring before reaching its facility).

Further, DEA counsel has since reaffirmed that there were no physical security issues, thefts or losses, or diversion of any pharmaceutical products from Inmar’s Grand Prairie facility. DEA counsel confirmed this at a prehearing conference before the DEA Chief Administrative Law Judge on November 14, 2023.

IT REMAINS BUSINESS AS USUAL AT INMAR

We are continuing to operate at full capacity on a go-forward basis with no expectation that our operational capacity will be limited in any way. Inmar has made material progress with the DEA in ongoing settlement discussions, and the DEA renewed the Inmar Rx Solutions registration in October 2023.

Inmar is actively working to resolve this matter with DEA as soon as possible and implementing remedial measures that go above and beyond federal requirements for DEA registrants.

We are operating at full capacity while we work towards a resolution with our partners at the DEA.

Our Grand Prairie, TX facility was designed and built in close collaboration with the DEA to ensure the highest level of safety, security and compliance, and we are always exploring new options and adding controls to further improve our operations.

We have a high degree of redundancy built into our security protocols and systems with a focus on precision, control and elevating excellence. Our industry-leading protocols include:

  • role-based system access;
  • pocketless uniform requirements;
  • up to 700 random frisk searches per shift;
  • 23 quality control validation points measuring adherence to over 290 operating procedures;
  • 200+ high resolution cameras; and
  • detailed facility mapping for every bottle, box or syringe.

Inmar has a long-term partnership with the DEA, and we’ve worked closely together on matters related to security and surveillance measures for handling controlled substances.